Why GLP-1 Alone Is No Longer Enough
GLP-1 receptor mono-agonism — the mechanism underlying semaglutide (Ozempic/Wegovy) — has reached a practical ceiling of approximately 15% body weight reduction, a plateau that has driven the entire next-generation obesity pharmacology field toward multi-receptor strategies. Drucker and Nauck (2023) describe this evolution as a deliberate progression: from GLP-1 mono-agonism, through GLP-1/GIP dual agonism (tirzepatide), toward amylin co-targeting as the next logical step in incretin pharmacology.
The obesity treatment benchmark is shifting. Batterham and Wharton (2024) note that 15–20% average weight loss is the emerging standard for next-generation agents, with amycretin’s Phase II data placing it squarely within that range. Obesity affects hundreds of millions of people globally, and according to WHO, it is a primary driver of type 2 diabetes, cardiovascular disease, and all-cause mortality — making the case for more effective pharmacotherapy urgent.
The rationale for combining GLP-1 and amylin receptor activation is mechanistic, not incremental. These two systems engage non-overlapping neural circuits: GLP-1 acts primarily via vagal afferents and the nucleus tractus solitarius (NTS), while amylin activates circumventricular organs — specifically the area postrema — enabling additive suppression of food intake when both pathways are co-activated simultaneously. This is not a dosing escalation of an existing mechanism; it is the recruitment of an entirely separate satiety system.
The functional amylin receptor is formed by the calcitonin receptor (CALCR) in complex with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3). The three CALCR/RAMP isoforms differ in downstream signaling properties and tissue distribution. Area postrema and hypothalamic expression — including arcuate nucleus and dorsomedial hypothalamus — are most relevant to satiety and energy homeostasis, as described by Christopoulos and Hay (2022) and Potes and Lutz (2023).
The Dual CNS Satiety Mechanism That Sets Amycretin Apart
Amycretin achieves superior weight reduction compared to GLP-1 mono-agonism by simultaneously engaging two anatomically distinct satiety circuits in the central nervous system. GLP-1 receptor activation suppresses appetite primarily through nucleus tractus solitarius neurons and vagal afferent signalling; amylin receptor activation works through a separate pathway — area postrema neurons projecting to the hypothalamus — that activates pro-opiomelanocortin (POMC) neurons and suppresses the orexigenic NPY/AgRP circuit.
Preclinical rat studies demonstrate that dual GLP-1/amylin receptor agonism produces 18–22% body weight reduction, compared to 10–12% with GLP-1 receptor agonism alone, attributed to complementary activation of nucleus tractus solitarius and area postrema satiety circuits (Hayes and Grill, 2023).
Potes and Lutz (2023) confirmed that amylin receptor (CALCR/RAMP1-3) expression in the arcuate nucleus, dorsomedial hypothalamus, and area postrema directly activates POMC neurons while suppressing NPY/AgRP — synergizing with GLP-1 receptor signalling in the NTS. This dual-circuit engagement is the mechanistic foundation for why amycretin’s preclinical weight loss data exceed those of GLP-1 mono-agonism by a substantial margin.
“Dual GLP-1/amylin agonism achieves 18–22% body weight reduction in preclinical models versus 10–12% with GLP-1 alone — a difference explained by the simultaneous recruitment of area postrema and NTS satiety circuits.”
Beyond weight reduction, Marso and Holman (2024) report early clinical data indicating GLP-1/amylin co-agonism reduces systolic blood pressure, triglycerides, and improves insulin sensitivity beyond GLP-1 alone. The mechanism is attributed partly to amylin-mediated suppression of postprandial glucagon and direct cardiovascular receptor expression. Holst and Vilsboll (2024) further note that amylin receptor agonism independently suppresses postprandial glucagon, complementing GLP-1R-mediated insulin secretion enhancement — a finding with direct implications for the anticipated type 2 diabetes co-indication development pathway.
Amylin receptor agonism activates POMC neurons and suppresses NPY/AgRP orexigenic circuits in the arcuate nucleus and dorsomedial hypothalamus, synergizing with GLP-1 receptor signalling in the nucleus tractus solitarius — the mechanistic basis for amycretin’s superior weight reduction versus semaglutide (Potes and Lutz, 2023).
From Phase I to Phase II: The Clinical Evidence for Amycretin
Amycretin’s clinical development has produced consistent weight loss signals across both subcutaneous and oral formulations, with an adverse event profile that mirrors the established tolerability pattern of GLP-1 receptor agonists. Phase I data (Knudsen, Enebo et al., 2024) established the pharmacokinetic foundation: a half-life supporting once-weekly subcutaneous dosing, linear pharmacokinetics, and a 13.1% mean body weight reduction at 12 weeks in the highest dose cohort — achieved with predominantly gastrointestinal adverse events (nausea, vomiting) consistent with GLP-1R mechanism engagement.
Track amycretin patents, clinical filings, and competitor moves in real time with PatSnap Eureka.
Explore Amycretin Intelligence in PatSnap Eureka →The Phase II randomised controlled trial (Enebo, Knudsen, Holst et al., 2024) enrolled adults with obesity (BMI ≥30 kg/m²) and reported the primary endpoint — body weight change at 26 weeks — as a mean 15.2% reduction in the highest dose arm versus 1.8% for placebo. Secondary endpoints included statistically significant reductions in waist circumference, HbA1c, and fasting glucose, supporting the anticipated type 2 diabetes co-indication pathway. The adverse event profile was described as similar to semaglutide, providing a well-understood tolerability reference for regulatory review.
The Oral Formulation: Proof-of-Concept Established
The oral amycretin programme applies SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) technology — the same absorption-enhancer mechanism underlying oral semaglutide (Rybelsus) — to enable gastric absorption of the dual-agonist peptide. Chemical modifications including lactam bridges address peptide stability in the gastric environment. Phase II data (Rosenstock, Davies et al., 2024) from the once-daily tablet demonstrated 10.4% body weight reduction at 12 weeks versus 1.5% placebo, establishing proof-of-concept for oral GLP-1/amylin dual agonism. Gastrointestinal adverse events — nausea in 38% and vomiting in 12% of participants — were consistent with the mechanism.
Novo Nordisk’s 2024 SNAC-based oral delivery patent confirms linear pharmacokinetics in Phase I clinical subjects, supporting dose prediction for Phase II dose-finding. Both SC and oral amycretin formulations are described as supporting advancement toward Phase III, with Phase III readiness for the oral formulation being assessed separately from the subcutaneous programme.
A 52-week preclinical durability study (Skovbjerg, Larsen et al., 2024) in diet-induced obese mice demonstrated that amycretin treatment prevents weight regain after initial loss more effectively than semaglutide alone, attributed to persistent amylin receptor-mediated hypothalamic tone. Body fat percentage reduction reached 42% versus 28% for semaglutide at equivalent doses. These findings support the long-term durability hypothesis central to Phase III design, according to FDA guidance requirements for obesity drug approval programmes.
In a Phase II randomised controlled trial, subcutaneous amycretin produced a mean body weight reduction of 15.2% at 26 weeks in adults with obesity (BMI ≥30 kg/m²) in the highest dose arm, compared to 1.8% for placebo, with statistically significant reductions in waist circumference, HbA1c, and fasting glucose (Enebo, Knudsen, Holst et al., 2024).
Novo Nordisk’s Patent Estate and the Competitive IP Landscape
Novo Nordisk holds the broadest portfolio of GLP-1/amylin co-agonist patent claims in the field, with composition-of-matter filings covering amycretin structural analogs spanning 2020–2023 across WO, EP, and US jurisdictions. Patent landscape analysis by Becker and Fischer (2024) identifies Novo Nordisk as the dominant IP holder in this space, with claims extending from molecular scaffolds through to delivery device formulations.
The core composition-of-matter estate rests on three structural pillars, as documented in retrieved Novo Nordisk patent filings. First, the 2022 WO patent establishes foundational claims on GLP-1/amylin co-agonist peptide compositions demonstrating superior weight loss versus GLP-1 mono-agonism in preclinical models. Second, the 2023 WO patent on peptide backbone architectures claims C18 or C20 fatty acid linkers via γGlu-miniPEG spacers for albumin binding, achieving a 160–180 hour half-life in minipig pharmacokinetic studies — the structural basis for once-weekly dosing. Third, the 2023 EP patent introduces non-standard amino acid substitutions for protease resistance, achieving low nanomolar binding affinities (Ki) at both GLP-1R and CALCR/RAMP receptors.
The formulation estate extends the protection perimeter. A 2024 WO patent on SNAC-based oral delivery claims pharmaceutical compositions combining the dual-agonist peptide with the SNAC absorption enhancer, with gastric stability conferred by lactam bridges. A 2023 US patent on prefilled pen delivery claims specific buffer, surfactant, and preservative concentrations for storage stability in glass pen cartridges, with stability demonstrated at 5°C for 24 months. Dosing regimen patents (2023 WO) claim dose escalation schedules to mitigate GI tolerability — a standard but commercially significant element of the IP estate. According to EPO patent data, Novo Nordisk’s incretin-related filings have accelerated substantially since 2020.
Map the full Novo Nordisk amycretin patent estate and identify white-space opportunities with PatSnap Eureka.
Analyse the IP Landscape in PatSnap Eureka →Competitive IP: Zealand Pharma and the Amylin Receptor Space
Zealand Pharma A/S represents the primary competing IP position in the amylin receptor targeting space. Zealand’s ZP8396 amylin receptor agonist (2023 WO patent) claims peptide modifications for CALCR/RAMP selectivity and protease resistance, forming the basis for GLP-1/amylin co-agonist combination programmes in partnership arrangements. Singh and Gutch (2024) note that amycretin’s single-molecule design represents a unique IP position distinct from CagriSema (Novo Nordisk’s own fixed-dose combination of cagrilintide and semaglutide), potentially enabling separate patent protection and a simplified regulatory pathway as a new molecular entity.
The broader competitive landscape, as reviewed by Muller and Wadden (2024), includes retatrutide (Eli Lilly, GLP-1/GIP/glucagon triple agonist), CagriSema (Novo Nordisk fixed-dose combination), and orforglipron (Pfizer, oral small-molecule GLP-1R agonist). Amycretin is distinguished from these by its single-molecule dual receptor engagement — combining both pharmacophores in one peptide chain rather than co-administering separate molecules or targeting a different receptor combination. As documented by WIPO patent filings, the single-molecule co-agonist approach is an increasingly contested IP space globally.
Phase III Design, Competitive Positioning, and Strategic Outlook
Anticipated Phase III trials for amycretin are expected to follow the regulatory framework outlined by Astrup and Rössner (2024) for next-generation obesity agents: 68–72 week primary endpoint trials with FDA-required ≥5% placebo-adjusted weight loss and superiority design. The programme is expected to include a cardiovascular outcomes trial (CVOT), pediatric extension studies, and a type 2 diabetes sub-indication — a multi-indication strategy consistent with semaglutide’s own approval trajectory.
The strategic logic for pursuing both obesity and T2D indications simultaneously is well-supported. Holst and Vilsboll (2024) review the complementary mechanisms: amylin receptor agonism independently suppresses postprandial glucagon while GLP-1R agonism enhances insulin secretion, providing dual glycaemic benefit. Dual indication development is projected to maximise commercial value and potentially accelerate regulatory review by enabling shared clinical infrastructure across programmes.
Within Novo Nordisk’s own portfolio, amycretin and CagriSema represent parallel strategies targeting the same biological rationale — GLP-1 plus amylin receptor co-activation — through different structural approaches. CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg weekly SC) achieved 15.6% weight loss at 32 weeks in Phase II and is currently in Phase III REDEFINE trials. Amycretin’s single-molecule design offers potential advantages in manufacturing complexity, dosing adherence, and regulatory classification as a new molecular entity — but the two assets may ultimately serve different patient segments or market positions rather than compete directly.
“Amycretin’s single-molecule dual receptor engagement potentially enables separate patent protection and a simplified regulatory pathway as a new molecular entity — a structural IP advantage over fixed-dose combination approaches.”
The emerging benchmark of 15–20% average weight loss for next-generation agents, noted by Batterham and Wharton (2024), positions amycretin’s Phase II data at the lower boundary of this range for the subcutaneous formulation. Phase III will need to confirm durability beyond 26 weeks, establish the cardiovascular safety profile required for CVOT design, and determine whether the oral formulation’s 10.4% at 12 weeks translates to competitive efficacy over longer treatment periods. The 52-week preclinical durability data — 42% body fat reduction versus 28% for semaglutide — provides a mechanistic rationale for long-term superiority, but clinical confirmation in Phase III will be decisive for the asset’s commercial trajectory. Innovation intelligence platforms such as PatSnap’s life sciences tools are increasingly used by R&D and IP teams to monitor competitor filings and clinical signals in real time across the obesity pipeline.